Duopharma Biotech Berhad, through its subsidiary Duopharma (M) Sendirian Berhad, has signed a five-year exclusive agreement with Taiwan-based Enimmune Corporation for the distribution and sale of vaccines in Malaysia.
Duopharma Biotech Berhad recorded cumulative revenue of RM482.24 million for the first half of FY2026 ended 30 June 2026, which saw the Group’s Profit Before Tax growing 32.1% year-on-year to RM79.71 million, while Profit After Tax rose 32.2% to RM60.59 million, compared to the corresponding period in the preceding year.
Duopharma Biotech Berhad officially launched the Flavettes Merdeka 2026 campaign today, themed ‘Flavettes Setia Menemani Setiap Generasi’ and featuring a multi-prong collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik.
Biocon Limited, an innovation-led global biopharmaceutical company, announced that its long-standing partner, Duopharma Biotech Berhad via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health, Malaysia, valued at over MYR 225 million this year.
Duopharma Biotech Berhad held its 25th Annual General Meeting today, capping a successful FY2025 ended 31 December 2025, that saw the Company growing its revenue by 14.5% to RM931.69 million, from RM813.70 million in FY2024.
Duopharma Biotech Berhad recorded resilient financial performance in the first quarter ended 31 March 2026, delivering a stronger Profit Before Tax (“PBT”) of RM 40.41 million, and Profit After Tax (“PAT”) of RM30.71 million, increasing 19.8% year-on-year, despite Q1FY2026 revenue of RM247.88 million dropping 5.7% compared to RM262.74 million in the same period last year.
Duopharma Biotech Berhad reported a revenue of RM931.69 million for the year ended 31 December 2025, up 14.5% compared to revenue of RM813.70 million in financial year 2024.
Duopharma Biotech Berhad has contributed approximately RM300,000 in support of the Program Sekolah Angkat MADANI in 2025. In the initiative, the Company is supporting four schools, namely Sekolah Kebangsaan Bukit Naga and Sekolah Kebangsaan Seksyen 24, both in Shah Alam, Sekolah Kebangsaan Batu Unjur in Klang and Sekolah Menengah Kebangsaan Dato’ Abu Bakar Baginda in Bangi.
Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
MoUs with Centre for Affordable Diagnostics & Therapeutics Limited and PAMOJA Therapeutics BV seek to repurpose anti-malarial drug artesunate for cancer therapy and other applications
Duopharma Biotech Berhad has appointed Encik Wan Amir-Jeffery Bin Wan Abdul Majid as Group Chief Executive Officer of Duopharma Biotech Berhad effective 1 October 2025. Prior to this appointment, Encik Wan Amir-Jeffery [52], was Duopharma Biotech’s Chief Executive Officer – Group Operations.
Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Kuala Lumpur – CCM Pharmaceuticals Sdn Bhd (CCMP), a subsidiary of CCM Duopharma Biotech Berhad (CCMD), and Biocon Sdn Bhd (a subsidiary of Biocon Ltd) have been awarded a Letter of Award (LOA) by the Ministry of Health (MOH) to supply Human Insulin to all government hospitals and clinics valued at RM300 million for three years until December 1, 2019.
Duopharma Biotech Berhad, through its subsidiary Duopharma (M) Sendirian Berhad, has signed a five-year exclusive agreement with Taiwan-based Enimmune Corporation for the distribution and sale of vaccines in Malaysia.
Duopharma Biotech Berhad recorded cumulative revenue of RM482.24 million for the first half of FY2026 ended 30 June 2026, which saw the Group’s Profit Before Tax growing 32.1% year-on-year to RM79.71 million, while Profit After Tax rose 32.2% to RM60.59 million, compared to the corresponding period in the preceding year.
Duopharma Biotech Berhad officially launched the Flavettes Merdeka 2026 campaign today, themed ‘Flavettes Setia Menemani Setiap Generasi’ and featuring a multi-prong collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik.
Biocon Limited, an innovation-led global biopharmaceutical company, announced that its long-standing partner, Duopharma Biotech Berhad via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health, Malaysia, valued at over MYR 225 million this year.
Duopharma Biotech Berhad held its 25th Annual General Meeting today, capping a successful FY2025 ended 31 December 2025, that saw the Company growing its revenue by 14.5% to RM931.69 million, from RM813.70 million in FY2024.
Duopharma Biotech Berhad recorded resilient financial performance in the first quarter ended 31 March 2026, delivering a stronger Profit Before Tax (“PBT”) of RM 40.41 million, and Profit After Tax (“PAT”) of RM30.71 million, increasing 19.8% year-on-year, despite Q1FY2026 revenue of RM247.88 million dropping 5.7% compared to RM262.74 million in the same period last year.